FR2278334B1 - - Google Patents

Info

Publication number
FR2278334B1
FR2278334B1 FR7522521A FR7522521A FR2278334B1 FR 2278334 B1 FR2278334 B1 FR 2278334B1 FR 7522521 A FR7522521 A FR 7522521A FR 7522521 A FR7522521 A FR 7522521A FR 2278334 B1 FR2278334 B1 FR 2278334B1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR7522521A
Other versions
FR2278334A1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai Co Ltd
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Publication of FR2278334A1 publication Critical patent/FR2278334A1/fr
Application granted granted Critical
Publication of FR2278334B1 publication Critical patent/FR2278334B1/fr
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/70—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
    • C07D311/72—3,4-Dihydro derivatives having in position 2 at least one methyl radical and in position 6 one oxygen atom, e.g. tocopherols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
FR7522521A 1974-07-18 1975-07-18 Esters d'acides carboxyliques aliphatiques de la vitamine e, leur procede de preparation et leur application Granted FR2278334A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP49081692A JPS6020388B2 (ja) 1974-07-18 1974-07-18 ビタミンｅ脂肪族カルボン酸エステルの合成法

Publications (2)

Publication Number Publication Date
FR2278334A1 FR2278334A1 (fr) 1976-02-13
FR2278334B1 true FR2278334B1 (fr) 1978-11-10

Family

ID=13753401

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7522521A Granted FR2278334A1 (fr) 1974-07-18 1975-07-18 Esters d'acides carboxyliques aliphatiques de la vitamine e, leur procede de preparation et leur application

Country Status (5)

Country Link
US (1) US4039559A (fr)
JP (1) JPS6020388B2 (fr)
DE (1) DE2532000C2 (fr)
FR (1) FR2278334A1 (fr)
GB (1) GB1511366A (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4221810A (en) * 1978-03-23 1980-09-09 Nisshin Flour Milling Co., Ltd. Antiulcer compounds
FR2420523A1 (fr) * 1978-03-23 1979-10-19 Nisshin Flour Milling Co Nouveaux derives acides et esters et leur application comme agents antiulcere
US5502224A (en) * 1991-06-04 1996-03-26 Marigen, S.A. Biotenside esters and phosphatides with vitamin-D and vitamin-E compounds
CH681152A5 (de) * 1991-06-04 1993-01-29 Marigen S.A. Neue biotenside und antitumorale ester und phosphatide mit vitamin-d- und vitamin-e-verbindungen, ihre herstellung und aufarbeitung zu spontan dispergierbaren konzentraten.
EP0636618A1 (fr) * 1991-06-04 1995-02-01 Marigen S.A. Concentrés spontanément dispersibles et microémulsions contenant des esters formés avec des composés de vitamine-E, pour la préparation de médicaments avec activité antitumorale
KR950007045B1 (ko) * 1992-04-14 1995-06-30 주식회사태평양 폴리에톡실레이티드 비타민 e를 함유한 피부화장료
US5990322A (en) * 1999-03-09 1999-11-23 Sk Corporation Alpha-tocopherol cyclopropylates, the new vitamin E derivatives and method for producing the same
EP1035120B1 (fr) * 1999-03-10 2003-07-30 SK Corporation Cyclopropylates d'alfa-tocophérol, les dérivés de vitamine E, et méthodes pour les préparer
CN1329387C (zh) * 1999-03-16 2007-08-01 Sk株式会社 α－维生素E环丙烷羧酸酯、维生素E衍生物及其制备方法
US8790727B2 (en) * 2000-12-05 2014-07-29 Tahitian Noni International, Inc. Morinda citrifolia and iridoid based formulations
US8574642B2 (en) 2000-12-05 2013-11-05 Tahitian Noni International, Inc. Antiviral Morinda citrifolia L. based formulations and methods of administration
US20110171333A1 (en) * 2000-12-05 2011-07-14 Bryant Wadsworth Morinda Citrifolia Based Antioxidant and Antimicrobial Formulations for Improved Color Stability and Increased Shelf Life of Various Meat Products
US20110217394A1 (en) * 2000-12-05 2011-09-08 Brett Justin West Iridoid Based Formulations
US7244463B2 (en) * 2005-10-18 2007-07-17 Tahitian Noni International, Inc. Garcinia mangostana L. enhanced animal food product
US20070196527A1 (en) * 2006-02-23 2007-08-23 Jensen Claude J Preventative and treatment effects of Morinda citrifolia on Osteoarthritis and its related conditions
US7048952B2 (en) * 2002-05-21 2006-05-23 Morinda, Inc. Formulation for inhibiting fungal and microbial growth comprising morinda citrifolia puree juice
US20040192761A1 (en) * 2003-03-25 2004-09-30 Palu Afa Kehaati Preventative and treatment effects of morinda citrifolia as an aromatase inhibitor
US20120237626A9 (en) * 2000-12-05 2012-09-20 Palu Afa Kehaati Profiles of lipid proteins and inhibiting HMG-CoA reductase
US6855345B2 (en) * 2001-11-02 2005-02-15 Morinda, Inc. Preventative and treatment effects of Morinda citrifolia on diabetes and its related conditions
US8652546B2 (en) 2007-09-06 2014-02-18 Tahitian Noni International, Inc. Morinda citrifolia based formulations for regulating T cell immunomodulation in neonatal stock animals
US7018662B2 (en) * 2001-04-17 2006-03-28 Morinda, Inc. Palliative effects of morinda citrifolia oil and juice
US7070813B2 (en) * 2001-11-02 2006-07-04 Morinda, Inc. Preventative and treatment effects of morinda citrifolia as a colon cancer cell growth inhibitor
US20110160057A1 (en) * 2001-11-14 2011-06-30 Bryant Wadsworth Morinda Citrifolia Based Antimicrobial Formulations
US7442395B2 (en) * 2002-11-14 2008-10-28 Tahitian Noni International, Inc. Formulation for treating candidiasis using Morinda citrifolia
US6716873B1 (en) * 2003-03-20 2004-04-06 Yasoo Health Inc. Tocopherol ester compounds
US20060269630A1 (en) * 2003-04-16 2006-11-30 Palu Afa K Morinda citrifolia as a 5-Lipoxygenase inhibitor
US20050106275A1 (en) * 2003-05-02 2005-05-19 Chen Su Morinda citrifolia-based formulation for inhibiting metastasis of carcinogenic cells
JP4073826B2 (ja) * 2003-06-04 2008-04-09 タヒチアン ノニ インターナショナル インコーポレーテッド ヤエヤマアオキの抽出物を含む農業用活力剤
US20070259060A1 (en) * 2003-08-12 2007-11-08 Mian-Ying Wang Formulations and Methods for Treating Breast Cancer with Morinda Citrifolia and Methylsulfonymethane
US20050260291A1 (en) * 2004-03-10 2005-11-24 Palu Afa K Methods and compositions for reactivating acetylcholinesterase
WO2006028826A2 (fr) * 2004-09-01 2006-03-16 Paulus Wang Formulations a base de morinda citrifolia et procedes de gestion du poids
US20060141076A1 (en) * 2004-11-01 2006-06-29 Palu Afa K Morinda citrifolia based compositions and methods for inhibiting xanthine oxidase
US20060204601A1 (en) * 2005-03-09 2006-09-14 Palu Afa K Formulations and methods for preventing and treating substance abuse and addiction
US20060222716A1 (en) * 2005-04-01 2006-10-05 Joseph Schwarz Colloidal solid lipid vehicle for pharmaceutical use
US20060280818A1 (en) * 2005-05-26 2006-12-14 Palu Afa K Nicotinic acetylcholine receptor antagonist
US20070122507A1 (en) * 2005-05-26 2007-05-31 Palu Afa K Histone deacetylase and tumor necrosis factor converting enzyme inhibition
US20070154579A1 (en) * 2005-11-29 2007-07-05 Palu Afa K Morinda Citrifolia Based Formulation And Methods For Weight Management
US20070237848A1 (en) * 2005-12-21 2007-10-11 Brad Rawson MORINDA CITRIFOLIA BASED COMPOSITIONS FOR TREATMENT OF ANTI-INFLAMMATORY DISEASES THROUGH INHIBITION OF COX-1, COX-2, INTERLEUKIN-1beta, INTERLEUKIN-6, TNF-alpha, HLE, AND iNOS
US20070281903A1 (en) * 2006-05-04 2007-12-06 Palu Afa K Morinda Citrifolia-Based Formulation 5-LOX And 15-LOX
US8535741B2 (en) 2006-05-12 2013-09-17 Morinda, Inc. Method and composition for administering bioactive compounds derived from Morinda citrifolia
US8025910B2 (en) 2006-05-12 2011-09-27 Tahitian Noni International, Inc. Method and composition for administering bioactive compounds derived from Morinda citrifolia
US20080226758A1 (en) * 2006-11-28 2008-09-18 Shixin Deng Lipoxygenase and Cyclooxygenase Inhibition
US20080213415A1 (en) * 2007-02-08 2008-09-04 Palu Afa K Treatment of Glaucoma and Diabetic Retinopathy with Morinda Citrifolia Enhanced Formulations
US20080317890A1 (en) * 2007-06-21 2008-12-25 Claude Jarakae Jensen Method for treating visual impairment through the prophylactic administration of a morinda citrifolia-based naturaceutical
US20090196944A1 (en) * 2008-02-01 2009-08-06 Brad Rawson Methods of Manufacture of Morinda Citrifolia Based Compositions for Treatment of Anti-Inflammatory Diseases through Inhibition of Cox-1, Cox-2, Interleukin -1beta, Interleukin-6, TNF-alpha, HLE, and iNOS
US20110206786A1 (en) * 2010-02-23 2011-08-25 Brett Justin West Acai and Iridoid Based Formulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH475977A (de) * 1965-10-12 1969-07-31 Hoffmann La Roche Verfahren zur Herstellung eines Chromanderivates
CH547278A (de) * 1971-01-11 1974-03-29 Hoffmann La Roche Verfahren zur herstellung von chromanderivaten.
JPS5118954B2 (fr) * 1972-02-04 1976-06-14
GB1394260A (en) * 1972-10-24 1975-05-14 Ici Ltd Esters of alpha-tocopherol

Also Published As

Publication number Publication date
DE2532000A1 (de) 1976-02-05
FR2278334A1 (fr) 1976-02-13
JPS6020388B2 (ja) 1985-05-21
US4039559A (en) 1977-08-02
JPS5111770A (en) 1976-01-30
DE2532000C2 (de) 1984-11-22
GB1511366A (en) 1978-05-17

Similar Documents

Publication Publication Date Title
FR2278334B1 (fr)
IN144241B (fr)
JPS50110359A (fr)
FR2291067B1 (fr)
FR2287534B3 (fr)
JPS50128640A (fr)
JPS5327654Y2 (fr)
JPS5317177Y2 (fr)
FR2288456B1 (fr)
JPS50150761A (fr)
JPS50100300A (fr)
JPS538247Y2 (fr)
JPS50151215U (fr)
JPS5179633U (fr)
JPS50114478A (fr)
JPS50114600A (fr)
JPS50130134A (fr)
JPS50149626A (fr)
JPS5139927U (fr)
JPS5161248U (fr)
JPS5182114U (fr)
CH1078575A4 (fr)
CH579211A5 (fr)
BG23119A1 (fr)
CH592210A5 (fr)

Legal Events

Date Code Title Description
ST Notification of lapse